Part 6 of our Deep GUNA Research series, for practitioners.
This article is written for a practitioner audience and reproduces clinical case reports published by GUNA and authored by Salvatore Matarese, M.D. It is educational and historical in nature and does not replace clinical judgement or personalised medical advice. The diabetes case below describes insulin adjustments made by a treating physician under ongoing hospital-linked paediatric supervision — it is not a protocol, and no change to insulin therapy should ever be made without the direct involvement of the patient's own treating physician.
The previous four articles in this series set out the theory and composition behind INET. This final article looks at two of GUNA's own published clinical case reports — the real-world observations that sit behind the primary and tertiary product groups covered earlier in this series.
Report 1: Male Infertility
This case is notable because, after four months of therapy, GUNA's authors observed not only a marked improvement and normalisation of the biological and cell condition of the patient's semen, but the patient's partner also became pregnant.
The patient discussed was 38 years old at the time of writing, married for four years, and joined the study in May 1995. He presented as sulphuric at the somatic level and phosphoric at the mental level. He brought the results of a semen analysis carried out in April 1995 to the initial examination.
Standard semen analysis, 13/4/95 (prior to treatment)
Comment: The analysis of fresh semen showed a framework of moderate-level Oligoasthenoteratozoospermia, which became more marked in the 2-hour reading, with mild Spermioleucocytosis.
GUNA's authors introduced PNEI therapy with "suis" organotherapies of the endocrine glands and internal organs, combined with Lymphokines and high-dilution hormono-therapy (GUNA), and with specific oligoelements including Zinc, Nickel and Selenium. Acidum Phosphoricum Homaccord®-Heel and Sepia Compositum (GUNA) were added. The patient underwent this treatment for approximately four months, and the semen analysis was repeated in September 1995.
Standard semen analysis, 25/9/95 (after ~4 months of therapy)
Comment: The analysis of fresh semen, and after 2 hours, showed a moderate level of Oligozoospermia with mild Spermioleucocytosis. Concentration, motility and morphology had all improved compared with the previous analysis.
In October 1995, the patient's partner presented with amenorrhoea, which proved to be due to pregnancy. A pelvic ultrasound scan carried out on 4/12/95 — corresponding to the 8th week of gestation — recorded: "a normoflexed uterine body of increased size, inside which a single living embryo was noted, with cardiac activity and a CRL of 13mm, which confirms an actual gestational age corresponding to the week of amenorrhoea reported. Placenta with diffused outline. Volume of amniotic fluid: normal."
On the same date, the patient underwent a further semen analysis.
Standard semen analysis, 4/12/95
As the authors note, this represented a further gradual improvement across all three analyses.
Report 2: Type 1 Diabetes Mellitus
GUNA's authors describe five subjects undergoing homotoxicological treatment, aged 10–13 (two males, three females), all suffering from Type 1 (insulin-dependent) Diabetes Mellitus diagnosed at state hospital organisations.
One male subject, referred to as M.M. and aged 12, had never been treated with insulin therapy, at his parents' request. This patient's glycaemic levels, monitored throughout the day, never exceeded 220 mg%. He underwent approximately 15 months of homotoxicological therapy, following the approach described across this series. As soon as the therapy began, glycaemia normalised over two months. The initial diet prescribed was 1,800 calories with 70g of carbohydrates; glycaemic levels were reported as normal on a diet of unrestricted glycidic content by the time of writing.
A second case, described by the authors as "even more interesting," involved a female subject aged 13, diagnosed with Type 1 Diabetes Mellitus since July 1995, who had been undergoing insulin therapy since diagnosis. Her parents, having learned from M.M.'s father that he no longer suffered from hyperglycaemia, asked the author to treat their daughter as well.
The treating physician visited the patient in late October 1995, and homotoxicological therapy commenced on 1 November 1995. The therapy was applied without altering the patient's existing insulin therapy, the glycidic content of her diet, or any other parameter. Insulin dosing and glycaemic monitoring throughout continued to be managed by the patient's parents, in accordance with the instructions of the paediatric hospital they had been in contact with from diagnosis.
Beginning of Homotox therapy
At the time of writing, GUNA's authors report that the patient was in a state of glycaemic balance without insulin. The alteration of insulin therapy over the November 1995–April 1996 period was assessed by the treating physician according to the extent of the hyperglycaemic episodes suffered by the patient, and the other four subjects in the case series also underwent a slow but continuous reduction in insulin over the same period, managed the same way.
GUNA's authors are explicit that they regard this area of research as being, at the time of writing, at a delicate and early stage: "Diabetes 1 = Chronic insulin therapy" was the finding of their bibliographical study, and the authors state that they deliberately did not go into the therapeutic details of the protocol in the original publication, as the evidence was still being gathered toward formal registration of the therapy within the limits Homotoxicology allows, with a stated commitment to expanding on the research if the results were confirmed.
We are reproducing GUNA's own published case data here for practitioner reference, exactly as it appears in the source material. It describes a single clinical team's intensively supervised paediatric case series from the 1990s, run in coordination with a hospital paediatric service that managed the ongoing insulin dosing and glycaemic monitoring throughout — it is not a general protocol, and any adjustment to a patient's insulin therapy must always be made by that patient's own treating physician, based on that physician's own monitoring.
Closing This Series
Across this series we have traced INET from its roots in Reckeweg's homotoxicology, through the PNEI research that reframed the endocrine, immune and nervous systems as a single interconnected network, to the full composition of the three INET product groups, and finally to two of GUNA's own published clinical case reports. What ties all of it together is the same underlying premise: that supporting the neuroendocrine axis directly, alongside whatever other therapy a patient is already receiving, gives the body's own regulatory systems a better foundation to work from.
Featured products
Guna K2F DIA
Adjunct neuroendocrine support for women with Type 1 diabetes.
Explore the full Guna Endocrinology range — INET compounds and neuroendocrine support built on GUNA’s PNEI research.
Not sure which remedy is right for you?
Try our Natural Remedy Finder, or contact our team for guidance.
Related reading
- K2F-DIA and K2M-DIA in Full: Composition and the Five Energy Movements Rationale
- The Foundations of INET: From Homotoxicology to the Neuroendocrine-Immune Network
- INET Pharmacology: The Two Therapeutic Methods and Full Clinical Indications
Source: GUNA, *From Homotoxicology to INET*, "Clinical Cases," by Salvatore Matarese, M.D.
Tags: Deep Guna Research, Guna Articles, Clinical Cases, K2F-DIA, K2M-DIA, Diabetes Support